All Stories

  1. RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions
  2. miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy
  3. Molecular Mechanisms Mediating the Transfer of Disease-Associated Proteins and Effects on Neuronal Activity
  4. Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
  5. α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner
  6. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells
  7. Protein phosphorylation in neurodegeneration: friend or foe?
  8. Phosphorylation Modulates Clearance of Alpha-Synuclein Inclusions in a Yeast Model of Parkinson's Disease
  9. Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease
  10. Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator
  11. Studying the Molecular Determinants of Protein Oligomerization in Neurodegenerative Disorders by Bimolecular Fluorescence Complementation
  12. MeCP2: a novel Huntingtin interactor
  13. Off-pathwayα-synuclein oligomers seem to alterα-synuclein turnover in a cell model but lack seeding capabilityin vivo
  14. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation
  15. Inhibition of formation of α-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease
  16. P4–053: Alpha‐synuclein oligomers can act as seed in a fibrillation assay but do not cause increased aggregation in living cells
  17. β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons
  18. PLK2 Modulates α-Synuclein Aggregation in Yeast and Mammalian Cells
  19. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration
  20. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease
  21. alpha-Synuclein and intracellular trafficking: impact on the spreading of Parkinson’s disease pathology
  22. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications
  23. Crystal Structure of kynurenine 3-monooxygenase - truncated at position 394 plus HIS tag cleaved.
  24. Cocrystal Structure of kynurenine 3-monooxygenase in complex with UPF 648 inhibitor(KMO-394UPF)
  25. Crystal Structure of kynurenine 3-monooxygenase (KMO-394)
  26. Crystal Structure of kynurenine 3-monooxygenase (KMO-396Prot)
  27. Crystal Structure of kynurenine 3-monooxygenase (KMO-396Prot-Se)
  28. Structural basis of kynurenine 3-monooxygenase inhibition
  29. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies
  30. Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system
  31. SIRT1 and SIRT2: emerging targets in neurodegeneration
  32. Assessing the Subcellular Dynamics of Alpha-synuclein Using Photoactivation Microscopy
  33. Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice
  34. Sirtuins in Biology and Disease
  35. The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival
  36. LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models
  37. Parkinson’s disease-associated mutations in DJ-1 modulate its dimerization in living cells
  38. SNCA (α-synuclein)-induced toxicity in yeast cells is dependent on Sir2-mediated mitophagy
  39. Epigenetic regulation of BACE1 in Alzheimer’s disease patients and in transgenic mice
  40. B10 The role of n-terminal phosphorylation in huntingtin's oligomerisation, aggregation and toxicity
  41. Epigenetics in Parkinson’s and Alzheimer’s Diseases
  42. Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice
  43. Highlights of the Keystone Symposium: sirtuins in metabolism, aging and disease
  44. Novel Molecular Therapeutics in Parkinson's Disease
  45. High-throughput study of alpha-synuclein expression in yeast using microfluidics for control of local cellular microenvironment
  46. Editorial on Special Topic: Sirtuins in Metabolism, Aging, and Disease
  47. SIRT2 as a Therapeutic Target for Age-Related Disorders
  48. Imaging Protein Oligomerization in Neurodegeneration Using Bimolecular Fluorescence Complementation
  49. Idebenone and Resveratrol Extend Lifespan and Improve Motor Function of HtrA2 Knockout Mice
  50. Synthesis and in vitro evaluation of fluorinated styryl benzazoles as amyloid-probes
  51. α-Synuclein modifies huntingtin aggregation in living cells
  52. Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice
  53. Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells
  54. Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy
  55. Convergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease
  56. Aggresome formation and segregation of inclusions influence toxicity of α-synuclein and synphilin-1 in yeast
  57. FlAsH illuminates Aβ aggregation
  58. Impaired Proteostasis Contributes to Renal Tubular Dysgenesis
  59. Assessment of the Efficacy of Solutes from Extremophiles on Protein Aggregation in Cell Models of Huntington’s and Parkinson’s Diseases
  60. Epigenetics in neurodegeneration: A new layer of complexity
  61. Visualization of cell-to-cell transmission of mutant huntingtin oligomers
  62. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
  63. Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
  64. Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
  65. Simple is good: yeast models of neurodegeneration
  66. Zooming into protein oligomerization in neurodegeneration using BiFC
  67. Synphilin-1 Enhances α-Synuclein Aggregation in Yeast and Contributes to Cellular Stress and Cell Death in a Sir2-Dependent Manner
  68. Sirtuins: Common Targets in Aging and in Neurodegeneration
  69. Synaptic Dysfunction in Parkinson’s Disease: From Protein Misfolding to Functional Alterations
  70. A non-invasive method based on saliva to characterize transthyretin in familial amyloidotic polyneuropathy patients using FT-ICR high-resolution MS
  71. Increased serum HSP70 levels are associated with the duration of diabetes
  72. The sour side of neurodegenerative disorders: the effects of protein glycation
  73. Current and Future Therapeutic Strategies for Parkinsons Disease
  74. P3.009 Aging and neurodegeneration: common targets, common hopes
  75. Dopamine-Induced Conformational Changes in Alpha-Synuclein
  76. Novel insights into alpha syynuclein intracellular dynamics
  77. Dopamine-Induced Conformational Changes in a-Synuclein
  78. Unraveling the role of A-synuclein phosphorylation in the etiology of parkinson's disease
  79. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
  80. From Mad Cows to Neurotic Yeast: Novel Molecular Approaches to Understand Neurodegeneration
  81. Therapeutic role of sirtuins in neurodegenerative disease
  82. Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
  83. CHIP Targets Toxic  -Synuclein Oligomers for Degradation
  84. Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
  85. Yeast as a model for studying human neurodegenerative disorders
  86. Yeast as a model for studying human neurodegenerative disorders
  87. Detection of Compounds That Rescue Rab1‐Synuclein Toxicity
  88. Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro
  89. Pharmacological inhibition of PARP-1 reduces α-synuclein- and MPP+-induced cytotoxicity in Parkinson’s disease in vitro models
  90. Mechanisms of Disease II: Cellular Protein Quality Control
  91. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra
  92. Protein Aggregation Disorders
  93. Small heat shock proteins protect against α-synuclein-induced toxicity and aggregation
  94. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases
  95. Stress Tolerance, Metabolism, and Development
  96. Yeast Cells as a Discovery Platform for Neurodegenerative Disease
  97. Molecular Genetics Approaches in Yeast to Study Amyloid Diseases
  98. Interactions Among α-Synuclein, Dopamine, and Biomembranes: Some Clues for Understanding Neurodegeneration in Parkinson's Disease
  99. Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology
  100. Prion protein gene polymorphisms in Saccharomyces cerevisiae